Oxaliplatin Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Oxaliplatin Market is segmented By Formulation Type (Lyophilized Powder, Aqueous Solutions), By Indication (Adjuvant Treatment of Stage III Colon Cancer, Treatment of Stage IV Colorectal Cancer, Others), By Application (Colorectal Cancer, Stomach cancer, Ovarian cancer), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Oxaliplatin Market Size

The global Oxaliplatin market size was valued US$ XX billion in 2022 and is estimated to reach US$ XX billion by 2031 growing at a high CAGR during the forecast period (2024-2031).  

Oxaliplatin is an anti-cancer medication indicated to treat colorectal cancer. It is a platinum-based drug belonging to the same family as that of cisplatin and carboplatin. Oxaliplatin acts by interfering with the development of DNA in a cell, thereby stopping it from dividing into new cells and kills it.

Oxaliplatin Market Scope

For More Insights Request Free Sample

Oxaliplatin Market Dynamics

The oxaliplatin market growth is driven by the growing incidence of Colorectal cancers, and changing  lifestyle, increasing geriatric population and extensive research in field of oncology are the major factors that are anticipated to boost the global oxaliplatin market during the forecast period.

Increasing incidence of Colorectal Cancers, is expected to drive the global oxaliplatin market during the forecast period.

The number of colorectal cancer cases worldwide has been increasing. As per the American Cancer Society (ACS) estimates, there will be around 101,420 new colon cancer cases, and around 44,180 new cases of rectal cancer are registered in the USA in 2019. As per the National Cancer Institute data, nearly 1,735,350 new cases of cancer were diagnosed in the U.K in 2018. The diagnosed incident colorectal cancer cases are expected to increase by 27.3% to 672,400 cases by 2037. This increase can be attributed to a low-fiber diet, obesity, alcohol, and tobacco consumption. The increase in the number of colorectal cases will add to the overall global oxaliplatin market.

Increased usage of biologics and targeted therapies is likely to hamper the global colorectal cancer drugs market.

Increased usage of biologics and targeted therapies is likely to hamper the market growth. Biologic therapy helps the body’s immune system fight against cancer rather than chemical drugs, which reduces the body’s immune power. Targeted therapies block the growth and spreading of colorectal cancer even in stage IV, where chemical drugs are ineffective. For instance, the FDA has approved some targeted therapies to treat colorectal cancer, including bevacizumab, cetuximab, and panitumumab. The advantages of biologics drugs and targeted therapies over conventional chemical drugs might negatively influence the market.

COVID-19 Impact Analysis

Due to the covid-19 pandemic outbreak, the market for global oxaliplatin market was seen to be down, due to the barriers in production and sales segments. Since the outbreak led to the shutdown of all manufacturing firms except for masks, sanitizers and ventilators. Hence, the drugs were manufactured less compared to previous years, during the outbreak.

Oxaliplatin Market Segmentation Analysis

The lyophilized powder segment is expected to hold largest share in this market segment

Lyophilization is a freeze-drying process, which is performed to extend the shelf life of a product. The oxaliplatin lyophilized powder injection is prepared using a specific lyophilization process to increase the stability of the drug, reduce the risk of side effects, and ensure a high degree of clinical usage. However, it is slightly expensive than the aqueous solution. The global average selling price of 100 mg intravenous injection is around USD 84 – USD 500. Sanofi offers ELOXATIN in a lyophilized powder form.

The adjuvant treatment of stage III colon cancer segment is expected to hold largest share in this market segment

In patients with stage III colon cancer, adjuvant chemotherapy with fluoropyrimidine combined with oxaliplatin (FOLFOX and XELOX) are considered the standard treatment and reduces the risk of recurrence and mortality, with a treatment duration that may be shortened from 6 to 3 months in certain situations allowing to limit toxicities, especially cumulative sensitive neuropathy.

The colorectal cancer segment is expected to hold largest share in this market segment

Colorectal cancer is the second leading cause of cancer deaths in the U.S. As per the data by the National Cancer Institute, nearly 1,735,350 new cases of cancer were diagnosed in the U.K. and 609,640 people were succumbed to the disease in 2018. According to the American Society of Clinical Oncology (ASCO), in 2019, nearly 45,600 adults in the U.S. were diagnosed with colorectal cancer.

The hospital pharmacies segment is expected to hold largest share in this market segment

The hospital pharmacies held the largest share in the global oxaliplatin market. This is mainly owing to increasing number of patients suffering from colorectal cancers which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, Increasing number of oncologists and healthcare professionals, specializing in the diagnosis of cancer at an early stage and providing proper treatment is also contributing to the growth of this segment.Also the medications can only be administrated by intravenously under supervision of medical practioners at these locations.

Oxaliplatin Market Geographical Share

North America region holds the largest market share of global oxaliplatin market

North America held a major share of the global oxaliplatin market and is expected to continue its dominance during the forecast period. In North America, the oxaliplatin market is projected to be driven by an increase in colorectal cancer cases and raising awareness of various treatment modalities for cancer. As per the U.S. Department of Health and Human Services in U.S., colorectal cancer represented 8.3% of all new cancer cases in 2019. According to the American Cancer Society, Inc. (ACS), in 2020, nearly 104,610 new colon and 43,340 cases of rectal cancer are expected to be diagnosed in the U.S., with nearly 53,200 deaths from colorectal cancer.

Oxaliplatin Market Companies and Competitive Landscape

The global oxaliplatin market is highly competitive with presence of global companies.  Some of the key players which are contributing to the growth of the market include Sanofi, Pfizer Inc, Fresenius Kabi D, Dr. Reddy’s laboratory, Sun Pharmaceutical Industries Ltd, Qilu Pharmaceutical Co., Ltd, Teva Pharmaceuticals USA, Inc, Jiangsu Aosaikang Pharmaceutical Co. Ltd, Mylan, Hospira, Nаnјіng Рhаrmасеutісаl Fасtоrу, Jiangsu Hengrui Medicine, Lunan Pharmaceutical, Hisun Pharmaceutical, Hainan Jinrui Pharmaceutical. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally.

Oxaliplatin Market Key Companies to Watch

Pfizer Inc. 

Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.

Product Portfolio: The Company’s portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.

Product: OXALIPLATIN injection, for intravenous use 50 mg (5 mg/mL) or 100 mg (5 mg/mL) in a single-dose vial for adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor and treatment of advanced colorectal cancer.

Why Purchase the Report?

• Visualize the composition of the oxaliplatin market segmentation by formulation type, application, indication, distribution channel and by region highlighting the key commercial assets and players.
• Identify commercial opportunities in oxaliplatin market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of oxaliplatin market - level 4/5 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in excel for the key product of all major market players

The global oxaliplatin market report would provide an access to an approx. 69 market data table, 61 figures and 200 pages. 

Target Audience

• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers